NCT05679739

Brief Summary

This single-center proof of concept study aims to assess the efficacy of a blood pressure strategy targeting person- and time-specific cerebral blood flow compared with standard-of-care using neuron-specific enolase as a quantitative biomarker of brain injury. Our central hypothesis is that an individualized blood pressure strategy targeting cerebral perfusion will reduce the extent of brain injury as indicated by changes in levels of neuron-specific enolase from baseline at 72 hours. To test this hypothesis, we will recruit 49 patients to an individualized blood pressure management strategy targeting cerebral blood flow, where optimal blood pressure will be serially calculated by the ICM+ brain monitoring software (Cambridge, UK) using inputs from transcranial Doppler ultrasound and near-infrared spectroscopy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
49

participants targeted

Target at P25-P50 for not_applicable

Timeline
3mo left

Started Aug 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Aug 2023Aug 2026

First Submitted

Initial submission to the registry

October 30, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 11, 2023

Completed
8 months until next milestone

Study Start

First participant enrolled

August 29, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Expected
Last Updated

May 16, 2025

Status Verified

March 1, 2025

Enrollment Period

1.9 years

First QC Date

October 30, 2022

Last Update Submit

May 13, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean change in neuron-specific enolase (NSE)

    The mean change in concentration of NSE from baseline levels to 72 hours post-ROSC.

    72 hours post ROSC

Secondary Outcomes (13)

  • Peak concentration of myocardial injury biomarker - High-sensitive troponin (hsTNT)

    Within 72hours of ROSC

  • Peak concentration of myocardial injury biomarker - N-terminal pro b-type natriuretic peptide (NT-proBNP)

    Within 72hours of ROSC

  • Peak concentration of renal function - Creatinine

    Within 72hours of ROSC

  • Peak concentration of renal injury biomarker - Proenkephalin A 119-159 (penKID)

    Within 72hours of ROSC

  • Peak concentration of renal injury biomarker - Biologically active adrenomedullin (bio-ADM)

    Within 72hours of ROSC

  • +8 more secondary outcomes

Other Outcomes (1)

  • Exploratory outcome - Digital neurocognitive assessment

    Through study completion, average of 12 months post OHCA

Study Arms (1)

Individualized blood pressure strategy

EXPERIMENTAL

Hemodynamic optimization performed to an individualized target mean arterial pressure in the first 72 hours post ROSC based on cerebral perfusion assessed serially.

Other: Individualized blood pressure strategy

Interventions

An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.

Individualized blood pressure strategy

Eligibility Criteria

Age21 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 21 years of age
  • Comatose defined as not being able to obey verbal commands and no verbal response to pain after sustained ROSC.

You may not qualify if:

  • ≥ 80 years old at time of enrolment
  • Pregnant patients
  • Limitations of care or life support therapy withdrawn within 24 hours of admission

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National University Heart Centre, Singapore

Singapore, Singapore

RECRUITING

MeSH Terms

Conditions

Out-of-Hospital Cardiac Arrest

Condition Hierarchy (Ancestors)

Heart ArrestHeart DiseasesCardiovascular Diseases

Study Officials

  • Shir Lynn Lim

    National University Hospital, Singapore

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2022

First Posted

January 11, 2023

Study Start

August 29, 2023

Primary Completion

August 1, 2025

Study Completion (Estimated)

August 1, 2026

Last Updated

May 16, 2025

Record last verified: 2025-03

Locations